While hormone therapy is not conventionally considered as a standard treatment for GBM, recent studies have presented its potential application in targeting nuclear hormone receptors for GBM treatment (Gonzalez-Mora and Garcia-Lopez, 2021; Rodríguez-Lozano et al, 2019). Here, NR0B1 is linked to glioblastoma.